S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:CTKB

Cytek Biosciences (CTKB) Stock Price, News & Analysis

$6.71
+0.08 (+1.21%)
(As of 03/28/2024 ET)
Today's Range
$6.60
$6.80
50-Day Range
$6.29
$9.15
52-Week Range
$3.80
$12.31
Volume
684,001 shs
Average Volume
892,300 shs
Market Capitalization
$877.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Cytek Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
34.1% Upside
$9.00 Price Target
Short Interest
Bearish
7.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of Cytek Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$135,400 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.11) to ($0.09) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.72 out of 5 stars

Medical Sector

707th out of 938 stocks

Analytical Instruments Industry

23rd out of 28 stocks

CTKB stock logo

About Cytek Biosciences Stock (NASDAQ:CTKB)

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

CTKB Stock Price History

CTKB Stock News Headlines

Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
CTKB Mar 2024 5.000 put
Cytek Biosciences Reports Full Year 2023 Earnings
Piper Sandler Keeps Their Buy Rating on Cytek Biosciences (CTKB)
The Latest Analyst Ratings for Cytek Biosciences
See More Headlines
Receive CTKB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/10/2022
Today
3/28/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:CTKB
Fax
N/A
Employees
676
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$10.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+34.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-12,150,000.00
Pretax Margin
-8.14%

Debt

Sales & Book Value

Annual Sales
$193.01 million
Book Value
$2.90 per share

Miscellaneous

Free Float
110,023,000
Market Cap
$877.80 million
Optionable
Optionable
Beta
1.41
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

CTKB Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytek Biosciences stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytek Biosciences in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CTKB shares.
View CTKB analyst ratings
or view top-rated stocks.

What is Cytek Biosciences' stock price target for 2024?

5 Wall Street research analysts have issued twelve-month price targets for Cytek Biosciences' stock. Their CTKB share price targets range from $7.00 to $10.00. On average, they expect the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 34.1% from the stock's current price.
View analysts price targets for CTKB
or view top-rated stocks among Wall Street analysts.

How have CTKB shares performed in 2024?

Cytek Biosciences' stock was trading at $9.12 at the beginning of 2024. Since then, CTKB stock has decreased by 26.4% and is now trading at $6.71.
View the best growth stocks for 2024 here
.

Are investors shorting Cytek Biosciences?

Cytek Biosciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 8,510,000 shares, an increase of 9.2% from the February 29th total of 7,790,000 shares. Based on an average daily volume of 731,300 shares, the short-interest ratio is presently 11.6 days. Approximately 7.1% of the company's shares are sold short.
View Cytek Biosciences' Short Interest
.

When is Cytek Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our CTKB earnings forecast
.

How were Cytek Biosciences' earnings last quarter?

Cytek Biosciences, Inc. (NASDAQ:CTKB) announced its earnings results on Wednesday, August, 10th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.01. The business had revenue of $40.16 million for the quarter, compared to analyst estimates of $41.34 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 1.43% and a negative net margin of 6.29%.

What ETF holds Cytek Biosciences' stock?

First Trust Nasdaq Lux Digital Health Solutions ETF holds 446 shares of CTKB stock, representing 0.46% of its portfolio.

What guidance has Cytek Biosciences issued on next quarter's earnings?

Cytek Biosciences issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $203.0 million-$213.0 million, compared to the consensus revenue estimate of $207.1 million.

When did Cytek Biosciences IPO?

Cytek Biosciences (CTKB) raised $248 million in an initial public offering (IPO) on Friday, July 23rd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share.

Who are Cytek Biosciences' major shareholders?

Cytek Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Brown Capital Management LLC (8.86%), Vanguard Group Inc. (8.77%), Vanguard Group Inc. (8.77%), New York State Common Retirement Fund (2.17%), Wellington Management Group LLP (0.95%) and Northern Trust Corp (0.88%). Insiders that own company stock include Jack Ball, Ming Yan, Patrik Jeanmonod, Ra Capital Management, LP and Wenbin Jiang.
View institutional ownership trends
.

How do I buy shares of Cytek Biosciences?

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CTKB) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners